# Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

> **NCT03263767** · PHASE2 · TERMINATED · sponsor: **Nantes University Hospital** · enrollment: 47 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Clofarabine
- **RADIATION:** Full body irradiation
- **DRUG:** Cyclophosphamide
- **DRUG:** Cyclophosphamide
- **OTHER:** stem cell transplantation
- **OTHER:** nuclear cells
- **DRUG:** Thymoglobulin Injectable Product

## Key facts

- **NCT ID:** NCT03263767
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-15
- **Primary completion:** 2021-10-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Security criteria (MTD)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263767, "Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03263767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*